大肠癌Kai-1/CD82基因外显子9区域突变的研究

Mutation of Kai-1/CD82 Gene in Colorectal Cancer

背景与目的:探讨Kai-1/CD82基因外显子9区域的突变在结直肠癌演进与转移中的意义。材料与方法:提取40例结直肠癌患者的肿瘤组织(24例无淋巴结转移,16例有淋巴结转移)DNA和RNA,PCR扩增DNA,测序判断Kai-1/CD82基因中外显子9区域的突变情况;RT-PCR后经测序Kai-1/CD82基因外显子9缺失情况。结果:40例组织标本中18例出现Kai-1/CD82基因突变;在有淋巴结转移的结直肠癌组织中,突变的频率明显高于无淋巴结转移的结直肠癌组织(P<0.05),在大肠癌中晚期(DukesC/D期)明显高于早期(DukesA/B期)(P<0.05),而Kai-1/CD82基因的突变频率与结直肠癌患者的年龄,性别,组织学类型以及分化程度无关(P>0.05)。结论:Kai-1/CD82基因突变可能与大肠癌演进、转移有关,检测其突变,可以为判断预后、指导临床治疗提供实验依据。

BACKGROUND ＆ AIM： To explore the significance of mutation of the exon 9 domain of Kai-1/ CD82 gene in the progression and metastasis of colorectal cancer （CRC） . MATERIALS AND METHODS： The mutation of the domain of exon 9 was detected by using PCR and judged by sequencing in 40 CRC. The deletion of exon 9 was identified by using RT-PCR and validated by sequencing. RESULTS： The mutation in the Kai-1/CD82 gene was found in 18 of 40 colorectal cases （45%） .The frequency of mutation was significantly higher in the colorectal tumors with lymphatic metastasis than those without（P 〈 0.05）, and in the advanced stage（Dukes C and D） than in the earlier stage （Dukes A and B） of the cancer （P 〈 0.05） . However, there was no significant difference of the mutation frequency when stratified by age and sex of the patients, histological type as well as the degree of differentiation of the CRC （P〉0.05）. CONCLUSION： The mutation of the Kai-1/CD82 gene was associated with the progression and metastasis of CRC. This can be used for assessing the progression and metatasis of colorectal cancer and for guiding clinical therapy.